IM156 granted fast track designation by FDA for idiopathic pulmonary fibrosis

IM156, is a protein complex 1 inhibitor that targets the oxidative phosphorylation pathway, required to drive fibrotic disease and tumour growth. It is the first potent PC1 inhibitor to complete Phase 1 with good tolerability.

Source:

Biospace Inc.